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By Ying Yuan1 and Guosheng Yin2
University of Texas and University of Hong Kong
We propose a new integrated phase I/II trial design to identify
the most efficacious dose combination that also satisfies certain safety
requirements for drug-combination trials. We first take a Bayesian
copula-type model for dose finding in phase I. After identifying a set
of admissible doses, we immediately move the entire set forward to
phase II. We propose a novel adaptive randomization scheme to fa-
vor assigning patients to more efficacious dose-combination arms. Our
adaptive randomization scheme takes into account both the point es-
timate and variability of efficacy. By using a moving reference to
compare the relative efficacy among treatment arms, our method
achieves a high resolution to distinguish different arms. We also con-
sider groupwise adaptive randomization when efficacy is late-onset.
We conduct extensive simulation studies to examine the operating
characteristics of the proposed design, and illustrate our method us-
ing a phase I/II melanoma clinical trial.
1. Introduction. Phase I trials usually aim to find the maximum toler-
ated dose (MTD) for an investigational drug, and phase II trials examine
the efficacy of the drug at the identified MTD. Traditionally, phase I and
phase II trials are conducted separately. There is a growing trend to integrate
phase I and phase II trials in order to expedite the process of drug develop-
ment and reduce the associated cost [Gooley et al. (1994); Thall and Russell
(1998); O’Quigley, Hughes and Fenton (2001); Thall and Cook (2004); and
Yin, Li and Ji (2006); among others]. The majority of these designs focus
on single-agent clinical trials.
Treating patients with a combination of agents is becoming common in
cancer clinical trials. Advantages of such drug-combination treatments in-
clude the potential to induce a synergistic treatment effect, target tumor cells
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with differing drug susceptibilities, or achieve a higher dose intensity with
nonoverlapping toxicities. Trial designs for drug-combination studies involve
several distinct features that are beyond the scope of methods for single-
agent studies. In single-agent trials, we typically assume that toxicity mono-
tonically increases with respect to the dose. However, in a drug-combination
dose space, it is difficult to establish such ordering for dose combinations.
Consequently, decision making for dose escalation or de-escalation is difficult
in drug-combination trials due to the unknown toxicity order. Another im-
portant feature that distinguishes drug-combination trials from single-agent
trials is the toxicity equivalent contour in the two-dimensional dose-toxicity
space. As a result, multiple dose combinations with similar toxicity may
be found in phase I drug-combination trials. For these reasons, single-agent
phase I/II designs cannot be directly applied to drug-combination trials.
In spite of a rich body of literature on phase I dose-finding designs for
drug-combination trials [Simon and Korn (1990); Korn and Simon (1993);
Kramar, Lebecq and Candalh (1999); Thall et al. (2003); Conaway, Dun-
bar and Peddada (2004); Wang and Ivanova (2005); and Yin and Yuan
(2009); among others], research on phase I/II designs has been very limited.
Recently, Huang et al. (2007) proposed a parallel phase I/II clinical trial
design for combination therapies, which, however, only targets MTDs with
a toxicity probability of 33% because the “3+3” dose-finding design [Storer
(1989)] is used in the phase I component.
Our research is motivated by a cancer clinical trial at M. D. Anderson
Cancer Center for patients diagnosed with malignant melanoma. The exper-
imental agents to be combined are decitabine (a DNA methyltransferase in-
hibitor, which has shown clinical activity in patients diagnosed with leukemia
or myelodysplastic syndrome) and a derivative of recombinant interferon
which has been used to treat cancer patients with advanced solid tumors.
The primary objective of the trial is to find the most effective, safe doses of
both drugs when used in combination to treat melanoma. For this trial, an
integrated phase I/II design is more plausible to speed up the drug discovery
and reduce the total cost.
Toward this goal, we propose a new seamless phase I/II design to identify
the most efficacious dose combination that also satisfies certain safety re-
quirements for oncology drug-combination trials. In the phase I part of the
trial, we employ a systematic dose-finding approach by using copula-type
regression to model the toxicity of the drug combinations. Once phase I is
finished, we take a set of admissible doses to phase II, in which patients are
adaptively randomized to multiple treatment arms corresponding to those
admissible doses. We propose a novel adaptive randomization (AR) proce-
dure based on a moving reference to compare the relative efficacy among the
treatments in comparison. Our AR has a high resolution to distinguish treat-
ments with different levels of efficacy and thus can efficiently allocate more
BAYESIAN PHASE I/II TRIALS WITH COMBINED DRUGS 3
patients to more efficacious arms. The proposed design allows us to target
any prespecified toxicity rate and fully utilize the available information to
make dose-assignment decisions.
The rest of the paper is organized as follows. In Section 2 we adopt a co-
pula-type probability model for toxicity and develop a new AR procedure
for seamless implementation of the phase I/II drug-combination trial design.
In Section 3 we apply our design to a melanoma clinical trial, and assess its
operating characteristics through extensive simulation studies. In Section 4
we extend the proposed design to accommodate trials with late-onset efficacy
using group sequential AR. We conclude with a brief discussion in Section 5.
2. Phase I/II drug-combination design.
2.1. Dose finding in phase I. For ease of exposition, consider a trial with
a combination of two agents, A and B; let ai be the prespecified toxicity
probability corresponding to Ai, the ith dose of drug A, with a1 < a2 <
· · · < aI ; and let bj be that of Bj , the jth dose of drug B, with b1 < b2 <
· · · < bJ . Before the two drugs are combined, each drug should have been
thoroughly investigated when administered alone. Given the relatively large
dose-searching space and the limited sample size in a drug-combination trial,
it is critical to utilize the rich prior information on ai and bj for dose finding.
Typically, the maximum dose for each drug in the combination is either the
individual MTD determined in the single-agent trials or a dose below the
MTD. Therefore, the specification of ai and bj is quite accurate because the
upper bounds aI and bJ are known.
We employ the copula-type regression in Yin and Yuan (2009) to model
the joint toxicity probability πij at the dose combination (Ai,Bj),
πij = 1−{(1− a
α
i )
−γ + (1− bβj )
−γ − 1}−1/γ ,(2.1)
where α,β, γ > 0 are unknown model parameters. This model satisfies the
natural constraints for drug-combination trials. For example, if the toxicity
probabilities of both drugs are zero, the joint toxicity probability is zero; and
if the toxicity probability of either drug is one, the joint toxicity probability
is one. Another attractive feature of model (2.1) is that if only one drug is
tested, it reduces to the well-known continual reassessment method (CRM)
for a single-agent dose-finding design [O’Quigley, Pepe and Fisher (1990)].
Although model (2.1) takes a similar functional form as the Clayton cop-
ula [Clayton (1978)], there are several fundamental differences [Yin and Yuan
(2010)]. Copula models are widely used to model a bivariate distribution by
expressing the joint probability distribution through the marginal distribu-
tions linked with a dependence parameter [for example, see Clayton (1978);
Hougaard (1986); Genest and Rivest (1993); and Nelsen (2006)]. In a drug-
combination trial, we in fact only observe a univariate dose-limiting toxicity
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(DLT) outcome for combined agents. For a patient treated by combined
agents (Ai,Bj), a single binary variable X indicates whether this patient
has experienced DLT: that is, X = 1 with probability πij , and X = 0 with
probability 1−πij . Therefore, model (2.1) is actually not a copula; we simply
borrow the structure of the Clayton copula to model the joint toxicity prob-
ability when the two drugs are administered together. Moreover, model (2.1)
is indexed by three unknown parameters (α,β, γ), in which γ is similar to
the dependence parameter in standard copula models and the two extra
parameters α and β render model (2.1) more flexibility to accommodate
the complex two-dimensional dose-toxicity surface for the purpose of dose
finding. Analogous to the CRM, the parameters α and β also account for
the uncertainty of the prespecification of the single-agent toxicity proba-
bilities ai and bj , thereby enhancing the robustness of our design to the
misspecification of these prior toxicity probabilities.
Suppose that at a certain stage of the trial, among nij patients treated at
the paired doses (Ai,Bj), xij subjects have experienced DLT. The likelihood
given the observed data D is
L(α,β, γ|D)∝
I∏
i=1
J∏
j=1
π
xij
ij (1− πij)
nij−xij .
In the Bayesian framework, the joint posterior distribution is given by
f(α,β, γ|D)∝ L(α,β, γ|D)f(α)f(β)f(γ),
where f(α), f(β) and f(γ) denote vague gamma prior distributions with
mean one and large variances for α, β and γ, respectively. We derive the full
conditional distributions of these three parameters and obtain their posterior
samples using the adaptive rejection Metropolis sampling algorithm [Gilks,
Best and Tan (1995)].
2.2. Adaptive randomization in phase II. Once the phase I dose finding
is complete, the trial seamlessly moves on to phase II for further efficacy
evaluation. Although the main purpose of phase I is to identify a set of
admissible doses satisfying the safety requirements, efficacy data are also
collected. Based on the efficacy data collected in both phase I and phase II,
each new cohort of patients enrolled in phase II are immediately randomized
to a more efficacious treatment arm with a higher probability. Similar to
most of the phase I/II trial designs, patients in phase I and phase II need to
be homogeneous by meeting certain eligibility criteria, such that the efficacy
data in phase I can be also used to guide adaptive randomization in phase II.
For ease of exposition, we assume that K admissible doses have been
found in phase I and will be subsequently assessed for efficacy using K par-
allel treatment arms in phase II. Let (p1, . . . , pK) denote the response rates
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corresponding to the K admissible doses, and assume that among nk pa-
tients treated in arm k, yk subjects have experienced efficacy. We model
efficacy using the Bayesian hierarchical model to borrow information across
multiple treatment arms:
yk|pk ∼ Bi(nk, pk),
pk ∼ Be(ζ, ξ),
(2.2)
ζ ∼Ga(0.01,0.01),
ξ ∼Ga(0.01,0.01),
where Bi(nk, pk) denotes a binomial distribution, and Be(ζ, ξ) denotes a be-
ta distribution with a shape parameter ζ and a scale parameter ξ. We take
vague gamma prior distributions Ga(0.01,0.01) with mean one, for both ζ
and ξ, to ensure that the data dominate the posterior distribution. The
posterior full conditional distribution of pk follows Be(ζ + yk, ξ + nk − yk),
but those of ζ and ξ do not have closed forms. As the trial proceeds, we
continuously update the posterior estimates of the pk’s under model (2.2)
based on the cumulating data.
The goal of response-AR is to assign patients to more efficacious treatment
arms with higher probabilities, such that more patients would benefit from
better treatments [Rosenberger and Lachin (2002)]. A common practice is
to take the assignment probability proportional to the estimated response
rate of each arm, for example, using the posterior mean of pk (k = 1, . . . ,K).
However, such an AR scheme does not take into account the variability of the
estimated response rates. At the early stage of a trial, there is only a small
amount of data observed, which would lead to widely spread and largely
overlapping posterior distributions of the pk’s. In this situation, the esti-
mated response rates of arms 1 and 2, say, pˆ1 = 0.5 and pˆ2 = 0.6, should not
play a dominant role for patient assignment, because more data are needed
to confirm that arm 2 is truly superior to arm 1. Nevertheless, at a later
stage, after more patients have been treated and a substantial amount of
data has become available, if we observe pˆ1 = 0.5 and pˆ2 = 0.6, we would
have more confidence in assigning more patients to arm 2, because its su-
periority would then be much more strongly supported. Thus, in addition
to the point estimates of the pk’s, their variance estimates are also critical
when determining the randomization probabilities.
To account for the uncertainty associated with the point estimates, one
can compare the pk’s with a fixed target, say, p0, and take the assignment
probability proportional to the posterior probability pr(pk > p0|D). How-
ever, in the case where two or more pk’s are much larger or much smaller
than p0, their corresponding posterior probabilities pr(pk > p0|D) are either
very close to 1 or 0, and, therefore, this AR scheme would not be able to
distinguish them.
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Recognizing these limitations of the currently available AR methods,
Huang et al. (2007) arbitrarily took one study treatment as the reference,
say, the first treatment arm, and then randomized patients based on Rk =
pr(pk > p1|D) for k > 1 while setting R1 = 0.5. For convenience, we refer
to this method as fixed-reference adaptive randomization (FAR), since each
arm is compared with the same fixed reference to determine the randomiza-
tion probabilities. By using one of the treatment arms as the reference, FAR
performs better than that using an arbitrarily chosen target as the refer-
ence. Unfortunately, FAR cannot fully resolve the problem. For example, in
a three-arm trial if p1 is low but p2 and p3 are high, say, p1 = 0.1, p2 = 0.4 and
p3 = 0.6, FAR may have difficulty distinguishing arm 2 and arm 3, because
both R2 and R3 would be very close to 1. Even with a sufficient amount of
data to support the finding that arm 3 is the best treatment, the probabili-
ties of assigning a patient to arm 2 and arm 3 are still close. This reveals one
limitation of FAR that is due to the use of a fixed reference: the reference
(arm 1) is adequate to distinguish arm 1 from arms 2 and 3, but may not
be helpful to compare arm 2 and arm 3. In addition, because R1 = 0.5, no
matter how inefficacious arm 1 is, it has an assignment probability of at
least 1/5, if we use R1/(R1 +R2 +R3) as the randomization probability to
arm 1. Even worse, in the case of a two-arm trial with p1 = 0.1, and p2 = 0.6,
arm 1 has a lower bound of the assignment probability 1/3, which is true
even if p1 = 0 and p2 = 1. This illustrates another limitation of FAR that
is due to the direct use of one of the arms as the reference for comparison.
Moreover, the performance of FAR depends on the chosen reference, with
different reference arms leading to different randomization probabilities.
To fully address the issues with available AR schemes, we propose a new
Bayesian moving-reference adaptive randomization (MAR) method that ac-
counts for both the magnitude and uncertainty of the estimates of the pk’s.
Unlike FAR, the reference in MAR is adaptive and varies according to the
set of treatment arms under consideration. One important feature of MAR
is that the set of treatments in comparison is continuously reduced, because
once an arm has been assigned a randomization probability, it will be re-
moved from the comparison set. By assigning randomization probabilities
to treatment arms on a one-by-one basis, we can achieve a high resolution
to distinguish different treatments through such a zoomed-in comparison.
Based on the posterior samples of the pk’s, we diagram the Bayesian MAR
in Figure 1 and describe it as follows:
1. Let A¯ and A denote the set of indices of the treatment arms that have
and have not been assigned randomization probabilities, respectively. We
start with A¯= {·} an empty set, and A= {1,2, . . . ,K}.
2. Compute the mean response rate for the arms belonging to the set A, p¯=∑
k∈A pk/
∑
k∈A 1, and use p¯ as the reference to determine Rk = pr(pk >
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Fig. 1. Diagram of the proposed moving-reference adaptive randomization for a three-
-arm trial. The top panels, from left to right, show that we first obtain posterior distri-
butions of p1, p2, p3 and p¯; then calculate Rk = pr(pk > p¯|D) for k = 1,2,3; and assign
the arm with the smallest value of Rk (i.e., arm 1) a randomization probability pi1. After
spending pi1, we remove arm 1 from the comparison set and distribute the remaining ran-
domization probability to the remaining arms (i.e, arms 1 and 2) in a similar manner, as
demonstrated in the bottom panels.
p¯|D), for k ∈ A. Identify the arm that has the smallest value of Rk,
Rℓ =mink∈ARk.
3. Assign arm ℓ a randomization probability of πℓ,
πℓ =
Rℓ∑
k∈ARk
(
1−
∑
k′∈A¯
πk′
)
,
and update A and A¯ by removing arm ℓ from A into A¯. Note that πℓ is
a fraction of the remaining probability 1−
∑
k′∈A¯ πk′ because the assign-
ment probability of
∑
k′∈A¯ πk′ has already been “spent” in the previous
steps.
4. Repeat steps 2 and 3 and keep spending the rest of the randomization
probability until all of the arms are assigned randomization probabilities,
(π1, . . . , πK), and then randomize the next cohort of patients to the kth
arm with a probability of πk.
The proposed MAR scheme has a desirable limiting property as given below.
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Theorem 2.1. In a randomized trial with K treatments, asymptotically,
MAR assigns patients to the most efficacious arm with a limiting probability
of 1.
The proof is briefly outlined in the Appendix. In contrast, using FAR,
the probability of allocating patients to the most efficacious arm may not
converge to 1.
2.3. Phase I/II trial design. The proposed phase I/II drug-combination
design seamlessly integrates each trial component discussed previously. Let φT
and φE be the target toxicity upper limit and efficacy lower limit, and let n1
and n2 be the maximum sample sizes for the phase I and phase II parts of
the trial, respectively. Let ce, cd, ca and cf be the fixed probability cutoffs
for dose escalation, de-escalation, dose admissibility and trial futility, the
values of which are usually calibrated through simulation studies such that
the trial has desirable operating characteristics. Our phase I/II design is
displayed in Figure 2 and described as follows:
1. In phase I, the first cohort of patients is treated at the lowest dose com-
bination (A1,B1).
2. During the course of the trial, at the current dose combination (Ai,Bj):
(i) If pr(πij < φT |D)> ce, the doses move to an adjacent dose combina-
tion chosen from {(Ai+1,Bj), (Ai+1,Bj−1), (Ai−1,Bj+1), (Ai,Bj+1)},
which has a toxicity probability higher than the current doses and
closest to φT . If the current dose combination is (AI ,BJ), the doses
stay at the same levels.
(ii) If pr(πij < φT |D)< cd, the doses move to an adjacent dose combina-
tion chosen from {(Ai−1,Bj), (Ai−1,Bj+1), (Ai+1,Bj−1), (Ai,Bj−1)},
which has a toxicity probability lower than the current doses and
closest to φT . If the current dose combination is (A1,B1), the trial
is terminated.
(iii) Otherwise, the next cohort of patients continues to be treated at the
current dose combination.
3. Once the maximum sample size in phase I, n1, is reached, suppose that
there are K dose combinations with toxicity probabilities πij satisfying
pr(πij < φT |D)> ca, then they are selected as admissible doses and car-
ried forward to phase II in parallel.
4. In phase II, MAR is invoked to randomize patients among the K treat-
ment arms. Meanwhile, the toxicity and futility stopping rules apply
to monitoring each arm: if pr(πk < φT |D) < ca (over-toxic), or pr(pk >
φE |D)< cf (futility), arm k is closed, k = 1, . . . ,K.
5. Once the maximum sample size in phase II, n2, is reached, the dose
combination that has the highest posterior mean of efficacy is selected as
the best dose.
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Fig. 2. Diagram of the proposed phase I/II trial design for drug-combination trials.
In the proposed design, the response is assumed to be observable quickly
so that each incoming patient can be immediately randomized based on
the efficacy outcomes of previously treated patients. This assumption can
be relaxed by using a group sequential AR approach, when the response is
delayed. The group sequential AR updates the randomization probabilities
after each group of patients’ outcomes become available rather than after
each individual outcome [Jennison and Turnbull (2000)]. Our design is suit-
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able for trials with a small number of dose combinations, because all the dose
combinations satisfying the safety threshold would be taken into phase II.
If a trial starts with a large number of dose combinations, many more doses
could make it into phase II, possibly some with toxicity much lower than the
upper bound. From a practical point of view, we could tighten the admis-
sibility criteria by choosing only those with posterior toxicity probabilities
closest to φT .
The proposed phase I/II drug-combination trial design has been imple-
mented using C++. The executable file is available for free downloading at
http://odin.mdacc.tmc.edu/˜yyuan/, and the source code is available upon
request.
3. Application.
3.1. Motivating trial. We use a melanoma clinical trial to illustrate our
phase I/II drug-combination design. The trial examined three doses of decita-
bine (drug A) and two doses of the derivative of recombinant interferon
(drug B). The toxicity upper limit was φT = 0.33, and the efficacy lower limit
was φE = 0.2. A maximum of 80 patients were to be recruited, with n1 = 20
for phase I, and n2 = 60 for phase II. In the copula-type toxicity model, we
specified the prior toxicity probabilities of drug A as ai = (0.05,0.1,0.2), and
those of drug B as bj = (0.1,0.2). We elicited prior distributions Ga(0.5,0.5)
for α and β, and Ga(0.1,0.1) for γ. The dose-limiting toxicity was defined
as any grade 3 or 4 nonhematologic toxicity, grade 4 thrombocytopenia,
or grade 4 neutropenia lasting more than two weeks or associated with
infection. The clinical responses of interest included partial and complete
response. In this trial, it took up to two weeks to assess both toxicity and
efficacy, rendering the response-adaptive randomization practically feasible.
The accrual rate was two patients per month, and thus no accrual suspen-
sion was needed to wait for patients’ responses in order to assign doses to
new patients. It took approximately 10 months to conduct the phase I part
and two and a half years to complete the phase II part of the trial. We
used ce = 0.8 and cd = 0.45 to direct dose escalation and de-escalation, and
ca = 0.45 to define the set of admissible doses in phase I. We applied the
toxicity stopping rule of pr(πk <φT |D)< ca and the futility stopping rule of
pr(pk > φE |D)< cf with cf = 0.1 in phase II. The decisions on dose assign-
ment and adaptive randomization were made after observing the outcomes
of every individual patient.
After 20 patients had been treated in the phase I part of the melanoma
trial, three dose combinations (A1,B1), (A1,B2) and (A2,B1) were identified
as admissible doses and carried forward to phase II for further evaluation
of efficacy. During phase II, the MAR procedure was used to allocate the
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Fig. 3. Adaptive randomization probabilities for the three admissible dose combinations
in the melanoma clinical trial.
remaining 60 patients to the three dose combinations. Figure 3 displays
the adaptively changing randomization probabilities for the three treatment
arms as the trial proceeded. In particular, the randomization probability of
(A2,B1) decreased first, and then increased; that of (A1,B2) increased first
and then decreased; and that of (A1,B1) kept decreasing as the trial pro-
gressed. At the end of the trial, the dose combination (A2,B1) was selected
as the most desirable dose with the highest estimated efficacy rate of 0.36.
3.2. Operating characteristics. We assessed the operating characteristics
of the proposed design via simulation studies. Under each of the 12 scenarios
given in Table 1, we simulated 1000 trials. In the Monte Carlo Markov
chain (MCMC) procedure, we recorded 2000 posterior samples for the model
parameters after 100 burn-in iterations.
In each scenario, the target dose-combination is defined as the most effica-
cious one belonging to the admissible set. We present the selection percent-
ages and the numbers of patients treated at all of the dose combinations.
Scenarios 1–4 represent the most common cases in which both toxicity and
efficacy increase with the dose levels, while the target doses are located
differently in the two-dimensional space. The target dose is (A3,B1) in sce-
nario 1, and (A2,B2) in scenario 2, which not only had the highest selection
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Table 1
Selection probability and number of patients treated at each dose combination using the
proposed phase I/II design, with the target dose combinations in boldface
Drug A Simulation results
True pr(toxicity) True pr(efficacy)
Drug Selection Number of
Sc. B 1 2 3 1 2 3 percentage patients
1 2 0.1 0.15 0.45 0.2 0.4 0.6 1.0 25.2 18.3 8.8 17.0 15.3
1 0.05 0.15 0.2 0.1 0.3 0.5 0.0 10.7 42.8 8.5 11.3 18.0
2 2 0.1 0.2 0.5 0.2 0.4 0.55 4.0 44.5 2.8 11.3 21.2 8.1
1 0.05 0.15 0.4 0.1 0.3 0.5 0.3 24.0 19.2 9.7 15.8 11.4
3 2 0.1 0.15 0.2 0.2 0.3 0.5 1.7 7.0 67.1 8.3 10.9 31.3
1 0.05 0.1 0.15 0.1 0.2 0.4 0.0 1.9 19.8 8.2 7.9 11.9
4 2 0.1 0.4 0.6 0.3 0.5 0.6 16.3 25.4 0.2 16.1 15.1 3.7
1 0.05 0.2 0.5 0.2 0.4 0.55 3.9 46.2 3.1 14.2 22.3 5.7
5 2 0.1 0.2 0.25 0.3 0.5 0.2 7.6 52.8 0.3 11.1 19.9 13.4
1 0.05 0.15 0.2 0.2 0.4 0.4 0.8 20.5 15.4 10.2 12.5 11.2
6 2 0.05 0.05 0.05 0.2 0.3 0.5 0.3 5.2 77.8 7.5 9.6 37.9
1 0.05 0.05 0.05 0.1 0.2 0.4 0.0 0.3 16.0 7.7 6.7 10.4
7 2 0.1 0.2 0.5 0.2 0.4 0.5 4.2 41.8 9.3 10.6 20.3 10.7
1 0.05 0.15 0.2 0.1 0.3 0.4 0.5 10.7 29.8 9.5 12.1 15.0
8 2 0.5 0.55 0.6 0.5 0.5 0.5 0.0 0.0 0.0 0.4 0.3 0.1
1 0.5 0.55 0.6 0.5 0.5 0.5 0.1 0.0 0.0 7.3 0.4 0.1
9 2 0.4 0.72 0.9 0.44 0.58 0.71 0.5 0.0 0.0 3.6 1.6 0.3
1 0.23 0.4 0.59 0.36 0.49 0.62 23.9 3.7 0.0 20.9 6.0 0.8
10 2 0.24 0.56 0.83 0.4 0.6 0.78 10.8 2.5 0.0 11.6 6.0 1.2
1 0.13 0.25 0.42 0.32 0.5 0.68 19.0 41.6 3.3 22.1 19.9 4.0
11 2 0.15 0.25 0.4 0.3 0.41 0.54 17.1 35.4 17.2 13.3 16.5 12.8
1 0.11 0.15 0.2 0.15 0.22 0.31 1.6 7.3 11.3 10.8 10.3 9.8
12 2 0.15 0.19 0.23 0.17 0.33 0.55 1.6 10.1 54.1 7.7 11.3 25.6
1 0.12 0.15 0.19 0.1 0.22 0.39 0.3 4.2 17.9 9.0 8.2 10.5
probability, but was also the arm to which most of the patients were ran-
domized. In scenario 3 the target dose is the combination of the highest
doses of drug A and drug B, for which the selection probability was close to
70%, and more than 30 patients were treated at the most efficacious dose.
Scenario 4 also demonstrated a good performance of our design with a high
selection probability of the target dose. In scenario 5 toxicity increases with
the dose but efficacy first increases then decreases, and in scenario 6 toxicity
maintains at a very low level, but efficacy gradually increases with the dose.
Under these two scenarios, both the selection probabilities and the numbers
of patients allocated to the target dose were plausible. Scenario 7 has two
target doses due to the toxicity and efficacy equivalence contours. In that
scenario, both the target doses were selected with much higher percentages
and more patients were assigned to those two doses than others. Scenario 8
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Table 2
Selection percentage of each dose combination to the admissible set and the average size
of the admissible set, K¯, in phase I. The true admissible doses are in boldface
% of admissible K¯ % of admissible K¯ % of admissible K¯
Scenario 1 Scenario 2 Scenario 3
97.8 95.2 67.9 5.4 97.9 92.2 38.2 4.9 99.6 99.0 91.8 5.9
98.1 98.0 91.9 98.8 98.2 72.6 99.7 99.7 98.3
Scenario 4 Scenario 5 Scenario 6
93.3 75.9 14.6 4.2 98.0 95.9 81.6 5.6 99.5 99.5 99.0 6.0
96.5 94.9 52.1 98.6 98.5 93.7 99.5 99.5 99.5
Scenario 7 Scenario 8 Scenario 9
97.9 94.6 55.6 5.3 2.0 0.9 0.3 0.1 24.9 10.5 0.4 1.2
98.8 98.5 86.1 3.1 2.4 0.9 42.7 36.6 11.6
Scenario 10 Scenario 11 Scenario 12
69.6 42.7 4.9 3.1 88.4 82.5 53.5 4.8 91.9 89.3 73.4 5.3
82.4 78.3 36.4 91.1 90.1 77.7 92.5 92.4 87.6
demonstrated the safety of our design by successfully terminating the trial
early when toxicity is excessive even at the lowest dose. Scenarios 9–12 are
constructed for a sensitivity analysis, which will be described in Section 3.3.
To better understand the performance of the phase I part of the proposed
design, in Table 2 we display the percentage of each dose being selected into
the admissible set, and the average number of admissible doses, K¯ , at the end
of phase I. In most of the cases, the selection percentages of the admissible
doses were higher than 90%, and the average number of admissible doses
determined by the proposed design was close to the true value. For example,
in scenario 1, the true number of admissible doses is 5, and our design, on
average, selected 5.4 admissible doses for further study in phase II.
As the number of admissible doses selected by phase I may vary from one
trial to another, the final trial results shown in Table 1 are jointly affected
by both the phase I and phase II parts of the design. To disassemble their
intertwining effects, we conducted a simulation study with a focus on the
adaptive randomization only. In particular, we considered a phase II trial in
which a total of 100 patients would be randomized to three treatment arms.
Table 3 shows the results based on 1000 simulated trials under eight different
scenarios. Scenarios 1–3 simulate cases in which the first arm has the lowest,
intermediate and highest efficacy, respectively. Scenarios 4–6 are constructed
in a similar setting, but the efficacy differences among the three arms are
much larger. Scenarios 7 and 8 consider cases in which one or two arms
are futile. In all of the scenarios, MAR allocated the majority of patients
to the most efficacious arm in a more efficient way than FAR. For scena-
rios 1, 3 and 8, in Figure 4 we show the randomization probabilities averaged
over 1000 simulations with respect to the cumulative number of patients
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Table 3
Number of patients randomized to each treatment arm using the fixed-reference adaptive
randomization (FAR) compared to the moving-reference adaptive randomization (MAR).
The most efficacious dose is in boldface
Response rate FAR MAR
Sc. Arm 1 Arm 2 Arm 3 Arm 1 Arm 2 Arm 3 Arm 1 Arm 2 Arm 3
1 0.1 0.2 0.3 27.7 31.8 40.6 12.5 29.0 58.5
2 0.2 0.1 0.3 40.5 17.2 42.4 27.3 13.0 59.7
3 0.3 0.1 0.2 61.1 13.7 25.2 58.4 13.1 28.5
4 0.1 0.3 0.6 23.3 33.8 42.9 5.5 13.3 81.3
5 0.3 0.6 0.1 34.4 54.6 11.0 13.9 80.5 5.5
6 0.6 0.3 0.1 82.2 12.5 5.3 81.8 12.8 5.3
7 0.01 0.4 0.6 21.0 38.7 40.3 3.7 20.6 75.7
8 0.01 0.01 0.5 25.8 25.1 49.1 5.3 5.3 89.4
using MAR and FAR, respectively. As more data are collected, MAR has
a substantially higher resolution to distinguish and separate treatment arms
than FAR in terms of efficacy. For example, in scenario 1 the curves are
adequately separated using MAR after 20 patients are randomized, but are
still not well spread even after enrolling 40 patients using FAR. Furthermore,
considering scenarios 4, 5 and 6, we see that the number of patients assigned
to the most efficacious arm (with a response rate of 0.6) using FAR changed
substantially from 42.9 to 82.2, whereas that number stayed approximately
the same as 81 when using MAR. This phenomenon indicates the invariance
of MAR and the sensitivity of FAR to the reference arm.
3.3. Sensitivity analysis. In the first sensitivity analysis, we examined
the robustness of the proposed design to model misspecifications. We gen-
erated true toxicity and efficacy probabilities from the logistic regression
model,
πij =
exp(β0 + β1ZAi + β2ZBj + β3ZAiZBj)
1 + exp(β0 + β1ZAi + β2ZBj + β3ZAiZBj)
,(3.1)
but applied models (2.1) and (2.2) for estimation. We took the standard-
ized doses of drugs A and B in model (3.1) as ZAi = (0.05,0.1,0.2) and
ZBj = (0.1,0.2). These cases are listed as scenarios 9–12 in Table 1. When
the models for toxicity and efficacy were misspecified, our design still per-
formed very well: the target dose combination was selected with the highest
probability and most of the patients were allocated to those efficacious dose
combinations.
In the second sensitivity analysis, we evaluated the impact of the prior
specifications using two more diffusive prior distributions for α and β under
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Fig. 4. Randomization probabilities of the proposed moving-reference adaptive random-
ization (MAR) and the fixed-reference adaptive randomization (FAR) under scenarios 1,
3 and 8 listed in Table 3.
scenarios 1–4. The simulation results in Table 4 using the more diffusive
priors are very close to those for scenarios 1–4 in Table 1. Therefore, the
proposed design does not appear to be sensitive to the prior specification.
4. Late-onset efficacy. In practice, toxicity and efficacy outcomes need
to be ascertainable shortly after the initiation of the treatment in order to
make a real-time decision on the treatment assignment for each incoming pa-
tient. Often, toxicity can be observed quickly; whereas efficacy is late-onset,
for example, tumor shrinkage may take a relatively long time to assess. Such
delayed efficacy outcomes pose new challenges to the use of AR in random-
ized trials. We propose using the group sequential AR procedure, which
adapts randomization probabilities after a group of patients’ outcomes be-
come available rather than after observing each individual’s outcome [Kar-
rison, Huo and Chappell (2003)]. More specifically, for the n2 patients to be
randomized toK treatment arms in phase II, we update the AR probabilities
after observing every m patients’ outcomes, 1≤m≤ n2. Choosing an appro-
priate m is critical for the practical performance of the group sequential AR.
With a larger value of m, the trial duration tends to be shortened because
we suspend the accrual less frequently, but it may downgrade the AR per-
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Table 4
Sensitivity analysis of the proposed Bayesian phase I/II drug-combination design under
different prior specifications
Selection percentage Number of treated patients
Sc. α,β ∼Ga(0.1,0.1) α,β ∼Ga(0.05,0.05)α,β ∼Ga(0.1,0.1) α,β ∼Ga(0.05,0.05)
1 2.0 21.0 25.4 2.0 19.9 27.1 7.8 15.7 20.2 7.7 15.7 20.8
0.1 8.2 41.8 0 9.0 40.2 7.4 9.6 18.3 7.1 9.6 18.1
2 5.4 46.5 2.9 4.9 45.9 3.7 10.6 21.6 9.6 10.5 21.4 9.4
0.4 21.0 20.3 0.2 22.9 17.9 8.8 14.4 13.0 8.8 14.9 12.5
3 2.0 6.3 69.6 0.9 6.1 70.2 7.2 10.1 36.3 6.8 9.8 36.4
0.1 1.2 19.4 0 1.4 19.9 7.1 6.5 12.1 7.0 6.6 12.5
4 16.9 24.7 0.2 15.6 24.6 0.3 15.2 16.4 4.0 15.1 16.0 4.3
4.8 44.2 2.8 4.1 45.1 3.0 13.1 20.6 6.8 13.2 20.4 6.2
formance. Using a smaller group size m, the group sequential AR procedure
would better facilitate assigning more patients to more efficacious treatment
arms, but it prolongs the trial duration. In addition to the group size, the
performance of the design also depends on the accrual rate, the length of the
follow-up required for efficacy assessment and the distribution of the time
to efficacy.
To evaluate our design using the group sequential AR, we took efficacy
to be late-onset, requiring three months for a complete evaluation. We con-
sidered six different group sizes: m= 1, 3, 6, 12, 20 and 30, corresponding
to 1.7%, 5%, 10%, 20%, 33.3% and 50% of the total sample size, n2 = 60,
in phase II. We investigated two different accrual rates: two and eight pa-
tients per month, and simulated four different patterns of the hazard for
the time to efficacy: increasing, constant, decreasing and hump-shaped over
time. The first three hazards were generated from the Weibull distribution,
and the hump-shaped hazard was generated from the log-logistic distribu-
tion. Other design parameters, such as φT , ce, cd and ca, took the same
values as those in Section 3.1.
Table 5 shows the number of patients allocated to the target dose com-
bination and the duration of the trial under the first five scenarios listed
in Table 1. In general, when the size of the sequential group m increases,
the number of patients allocated to the target dose combination gradually
decreases. This phenomenon was minor when m increased from 1 to 6, but
more notable when m became larger. For example, in scenario 1 with an in-
creasing hazard and an accrual rate of two patients per month, the numbers
of patients allocated to the target dose combination were 18.4, 17.7 and 15.0,
when m = 1,6 and 30, respectively. The trial duration was more sensitive
to the value of m, and changed dramatically when the size of the sequen-
tial group increased. When the accrual rate was two patients per month,
we observed a substantial decrease in the trial duration when m increased
from 1 to 6. For example, under scenario 2, the duration of the trial with
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Table 5
Number of patients allocated to the target dose combination and the trial duration (shown
as subscripts), with different group sizes m under scenarios 1–5
Hazard (accrual rate= 2/month) Hazard (accrual rate= 8/month)
m Increase Constant Decrease Hump Increase Constant Decrease Hump
Scenario 1
1 18.4157.8 18.1150.3 17.7139.5 17.8159.9 18.2149.4 17.5143.0 17.8131.5 17.4152.2
3 18.069.8 18.069.2 17.568.7 17.969.4 17.261.6 17.760.9 17.960.7 17.561.5
6 17.742.4 17.442.4 16.942.4 17.342.2 17.633.0 17.132.8 17.332.8 16.732.9
12 16.542.2 16.842.2 16.142.1 16.542.0 16.618.8 16.618.7 16.918.8 16.918.7
20 15.842.1 16.042.1 15.842.1 15.742.1 15.613.8 16.313.8 16.113.8 15.413.7
30 15.042.1 15.442.1 15.042.0 15.242.0 15.012.8 15.112.8 15.312.8 14.312.8
Scenario 2
1 21.0160.2 20.7153.7 22.5145.3 21.9162.3 21.3151.9 21.7146.9 22.0135.8 21.2154.5
3 20.869.5 21.669.4 21.968.6 21.569.2 21.361.3 21.261.2 21.560.8 20.961.1
6 20.742.3 21.142.1 21.742.2 20.942.1 20.732.8 21.632.7 21.832.6 20.932.6
12 20.542.0 20.842.0 21.242.1 20.941.9 20.518.6 20.818.6 21.018.7 20.618.7
20 20.242.0 19.142.1 20.242.0 20.842.1 20.013.7 19.313.7 20.113.8 19.613.7
30 19.142.2 19.642.1 19.641.9 19.742.1 18.612.8 19.612.8 18.512.8 19.312.8
Scenario 3
1 32.2161.2 32.0154.6 31.7144.7 31.1163.6 31.9153.8 32.0147.1 32.1136.6 32.3156.5
3 31.570.1 31.869.7 31.469.2 31.569.9 31.061.8 31.361.7 32.061.2 31.561.9
6 32.442.4 31.042.4 32.242.3 30.942.4 31.233.0 31.033.0 32.432.9 31.532.9
12 30.842.2 31.042.2 30.342.1 30.342.3 30.418.8 30.618.8 31.418.8 31.918.8
20 29.542.3 30.442.1 29.642.2 30.142.1 28.713.8 28.213.8 28.213.8 29.013.8
30 29.442.2 29.142.2 28.942.2 29.142.2 26.412.8 26.712.8 26.412.8 26.512.8
Scenario 4
1 23.0158.4 23.7151.5 22.8139.4 22.4159.5 23.5150.4 22.7143.8 22.3131.3 22.6151.9
3 22.769.1 22.368.9 22.668.7 22.469.1 22.361.0 22.860.9 21.959.8 21.061.2
6 21.842.4 21.742.2 22.542.3 21.342.3 22.232.6 21.932.8 22.432.9 21.532.7
12 21.242.1 21.341.9 20.742.1 21.041.8 20.418.6 22.018.7 21.918.7 21.218.7
20 20.242.1 20.342.1 19.842.0 20.142.0 20.013.7 20.113.7 19.913.7 20.313.8
30 19.342.2 19.342.1 18.642.1 19.442.2 19.512.8 19.212.7 20.212.8 18.912.8
Scenario 5
1 20.4159.7 21.3152.1 19.8141.1 20.3161.6 20.5152.4 20.5144.7 21.1133.4 20.9154.1
3 20.070.1 20.669.9 20.469.1 20.169.9 20.461.8 20.061.5 20.361.1 19.661.9
6 19.942.5 19.642.5 19.942.5 20.042.5 19.533.0 19.632.9 20.033.0 20.533.0
12 19.242.2 19.342.3 19.742.2 20.042.3 19.118.8 19.218.8 18.718.8 19.618.8
20 19.542.3 19.542.3 18.842.2 18.842.3 18.313.8 18.813.8 18.613.8 18.813.8
30 18.542.3 18.142.2 19.142.2 18.442.3 17.212.8 17.612.8 17.712.8 17.712.8
m= 6 was approximately 1/4 of that with m= 1. However, when we further
increased m from 6 to 30, the trial duration only changed slightly because
in this circumstance the trial duration was essentially dominated by the ac-
crual rate, which is typically a key factor affecting the trial duration. With
a higher accrual rate of eight patients per month, we observed additional
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reductions in the trial duration when m was larger than 6, but as a trade-off,
slightly fewer patients were allocated to the target dose combination.
In practice, trial duration is an important factor to be considered when
designing clinical trials. We should choose an appropriate group size so as to
achieve a reasonable balance between AR and the trial duration. It is worth
noting that the group size is mainly used to determine when to update the
randomization probabilities, not when to randomize patients. Patients are
randomized on a one-by-one basis to the treatment arms no matter the size
of the sequential group. In the extreme case that the group size equals the
total sample size, we essentially apply an equal randomization scheme.
5. Concluding remarks. Drug-combination therapies are playing an in-
creasingly important role in oncology research. Due to the toxicity equiva-
lence contour in the two-dimensional dose-combination space, multiple dose
combinations with similar toxicity may be identified in a phase I trial. Thus,
a phase II trial with AR is natural and ethical to assign more patients to
more efficacious doses. We have adopted a copula-type model to select the
admissible doses and proposed a novel AR scheme when seamlessly connect-
ing phase I and phase II trials. The attractive feature of this phase I/II design
is that once the admissible doses are identified, AR immediately takes effect
based on the efficacy data collected in the phase I study. The proposed de-
sign efficiently uses all of the available data resources and naturally bridges
the phase I and phase II trials. In our design, AR is based only on efficacy
comparison among admissible doses. It can be easily modified to take into
account both toxicity and efficacy by using their odds ratio as a measure
of the trade-off or desirability to adaptively randomize patients and select
the best dose combination at the end of the trial [Yin, Li and Ji (2006)].
The proposed design assumes that both toxicity and efficacy endpoints are
binary. In some cases, these endpoints can be ordinal or continuous, for
example, it may be more direct to treat the toxicity endpoint as an ordi-
nal outcome to account for multiple toxicity grades. To accommodate such
an ordinal toxicity outcome, we can take the approach of Yuan, Chappell
and Bailey (2007) by first converting the toxicity grades to numeric scores
that reflect their impact on the dose allocation procedure, and then incor-
porating those scores into the copula-type model using the quasi-binomial
likelihood. Another common scenario is that both toxicity and efficacy end-
points take the form of time-to-event measurements. In this case, various
survival models, such as the proportional hazards model, are available to
model the times to toxicity and efficacy. Along this direction, Yuan and
Yin (2009) discussed jointly modeling toxicity and efficacy as time-to-event
outcomes in single-agent trials; similar approaches can be adopted here for
phase I/II drug-combination trials.
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APPENDIX: PROOF OF THEOREM 2.1
The proposed moving-reference adaptive randomization procedure is in-
variant to the labeling of the treatment arms. Without loss of generality, we
assume that p1 < p2 < · · ·< pK , and determine the randomization probabil-
ity for arm 1. Starting with A= {1,2, . . . ,K}, p¯=
∑K
k=1 pk/K. As the num-
ber of subjects goes to infinity, it follows that the rank of Rk = pr(pk > p¯|D)
is consistent with the order of the pk’s, that is, R1 <R2 < · · ·<RK . There-
fore, for the first treatment arm ℓ= 1,
Rℓ =min
k∈A
Rk
= pr(p1 > p¯|D)
= pr{(p1 − p2) + (p1 − p3) + · · ·+ (p1 − pK)> 0|D}
≤ pr{(K − 1)(p1 − p2)> 0|D}
= pr(p1 > p2|D),
which converges to 0 asymptotically. Thus, π1 → 0, that is, the probability
of assigning patients to the least efficacious arm goes to zero. Following
similar arguments, we can show that πk → 0 for k = 2, . . . ,K− 1. Therefore,
the probability of allocating patients to the most efficacious arm, πK =
1−
∑K−1
k=1 πk, converges to 1.
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